4/A: Pasithea Therapeutics Director Corrects Stock Option Exercise Price in Amended SEC Filing

Emer Leahy, a director of Pasithea Therapeutics Corp., filed an amended Form 4 to correct the exercise price of a stock option granted on March 1, 2024.

Summary

• Emer Leahy, a director at Pasithea Therapeutics Corp., filed an amended Form 4 with the SEC.
• The amendment corrects the exercise price of a stock option granted on March 1, 2024, which was initially reported as $8.34 per share but should have been $8.13 per share.
• The stock option, for 7,500 shares, was granted under the company's 2023 Stock Incentive Plan and vests over three years.
• A reverse stock split of 1-for-20 was effected on January 2, 2024, which adjusted the share amounts and exercise prices of outstanding equity awards.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't indicate any significant positive or negative developments for the company.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. The correction of the exercise price suggests attention to detail in regulatory filings.

Stakeholder Impact

• The correction of the stock option exercise price ensures accurate reporting to shareholders.

Key Dates

Keywords

Form 4, Pasithea Therapeutics, Stock Option, Director, Emer Leahy, Amendment, Exercise Price, Reverse Stock Split